Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients with Chemorefractory KRAS G12C-mutated mCRC
Findings from the CodeBreaK 300 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate in Resectable Mucosal Melanoma
Findings from a phase II study
First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield Clinical-Pathologic Regression in Some Patients with High-Risk Oral Precancerous Disease
Findings from a phase II non-randomised controlled study in patients with high-risk oral proliferative verrucous leukoplakia
EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary Tract Carcinoma
New indication concerns a combination with gemcitabine and cisplatin in first-line treatment
FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients with Locally Advanced Unresectable or Metastatic HER2-positive Gastric Cancer
Updated indication restricts the use to patients whose tumours express PD-L1 CPS ≥ 1 as determined by an FDA-approved test
A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly Improves PFS in First-Line Treatment of Patients with EGFR-mutated Advanced NSCLC
Findings from the FLAURA2 study
Efficacy of Rituximab Maintenance in Patients with Mantle Cell Lymphoma Who Are MRD-negative After Induction
Findings from the European MCL Elderly study
EMA Recommends Extension of Indications for Talazoparib
New indications concerns a combination with enzalutamide for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated
A Combination of Trastuzumab with Gemcitabine and Cisplatin Shows Promising Activity in Patients with Treatment-Naïve HER2-positive Biliary Tract Cancer
Findings from the TAB study
FDA Approves Capivasertib with Fulvestrant for Breast Cancer
Evidence for efficacy is evaluated in CAPItello-291 study
PET Positivity After Two Cycles of ABVD Is Associated with a Worse Outcome in Localised Hodgkin Lymphoma Although Intensification with BEACOPPesc Is Safe
Final results of a preplanned analysis at a 10-year follow-up of H10 study
Efficacy Outcomes of Olaparib in Patients with mCRPC with BRCA Alterations Whose Disease Had Progressed on Next-Generation Hormonal Agent
Findings from an exploratory post hoc analysis of the subgroup of patients with BRCA alterations in PROfound study